SAN DIEGO, May 21, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will highlight its efforts to expand research and innovation surrounding its physiology technologies, including its Fractional Flow Reserve (FFR) and iFR® (Instant Wave-Free Ratio™) technologies, via various clinical and educational presentations and events at EuroPCR 2013 in Paris.
"Volcano is committed to making clinical and technological advances that expand access to functional management," commented Michele Perrino, president of Europe, Middle East, Africa, and India Operations of Volcano. "Our focus at EuroPCR is to introduce our latest functional management technologies and clinical data, and demonstrate their potential to improve both patient care and the experience for our physician partners in Europe. Given our commitment to provide physicians with choice, we are excited to feature iFR®, our novel hyperemia-free software modality, and our Verrata™ Pressure Guide Wire, which upon regulatory clearance will be our fifth new guide wire in five years."
Volcano will formally launch its iFR® modality and CORE® Integrated System, and display the Verrata™ Wire at the conference. Volcano will showcase its future and currently available physiology, imaging, and multi-modality systems products in the company's exhibit hall booth #M71.
Featured events for Volcano include four live case symposia demonstrating the benefits of incorporating both FFR and our iFR® modality in simple and complex cases, the presentation of the findings from the Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II) study data at a hot line session, and over 10 scientific podium presentations featuring advanced physiology using Volcano products.
Wednesday, May 22, 10:50 – 11:30 a.m.
Complex bifurcation stenting: LIVE demonstration of emerging techniques
LIVE iFR® demonstration from Erasmus University Medical Center, Thorax Center – Rotterdam, The Netherlands
Thursday, May 23, 9:45 - 11:45 a.m.
Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II)
Hot Line - Evolving procedural strategies
Thursday, May 23, 4:45 – 6:45 p.m.
Physiological Stenosis Assessment with FFR and Instant Wave-Free Ratio: We Need Both!
Live case demonstrations (simple and multivessel disease) from St. Thomas' Hospital, London, followed by panel discussions
Friday, May 24, 9:00 – 12:30 p.m.
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations
Continuous LIVE FFR and iFR® demonstrations from Sunninghill and Sunward Park Hospitals, South Africa and St Thomas' Hospital – London, United Kingdom
Daily, 12:00 – 3:00 p.m.
Meet the iFR® Experts
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Its products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements". Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; growth strategies; timing and achievement of product development milestones; outcome of ongoing litigation; the impact and benefits of market development; product introductions; unexpected new data, safety and technical issues; market conditions; and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Our iFR® software modality is approved in CE mark countries.
 Verrata™ Pressure Guide Wire is 510(k) and CE mark pending, and is not currently commercially available for sale.
SOURCE Volcano Corporation